Skip to main content
. 2021 Dec 16;138(24):2499–2513. doi: 10.1182/blood.2020010543

Figure 5.

Figure 5.

The CAR-HEMATOTOX score discriminates between a high risk and a low risk for hematotoxicity in 2 independent patient cohorts. (A-B) Univariate analysis comparing the CAR-HEMATOTOX score to the duration of severe neutropenia in the European (A) and (B) US validation cohorts. (C) ROC curves for the binary outcome of severe neutropenia between ≥4 and <14 days by CAR-HEMATOTOX score for the European and US validation cohorts. (D) Pooled analysis of the median duration of severe neutropenia (days 0-60) by CAR-HEMATOTOX score for both validation cohorts (n = 180); whiskers indicate the 95% CIs. (E) Relative distribution of clinical phenotypes of neutrophil recovery by CAR-HEMATOTOX score for the European validation cohort (n = 80). (F-G) Aggregated median ANC (F) and platelet count (G) over time for patients with a low or high score. The P value is provided for comparison of the calculated AUC for high-risk vs low-risk patients (supplemental Figure 6). Mann-Whitney U test ****P < .0001.